title: CD45RA expression by CD4 T lymphocytes in tumors invaded by B-cell non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD).
abstract: Little is known about the role of tumor infiltrating T lymphocytes (TIL-T) in the pathogenesis of malignant diseases and collaboration between normal and malignant cells has not yet been proved. In the present work, we have investigated whether immune T lymphocytes exist in tumors invaded by B-cell non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD). Therefore, we have studied the reactivity of the CD45RA monoclonal antibody, which discriminates between naive and memory CD4 T lymphocytes. Our results showed far lower percentages of CD4+ CD45RA+ in malignant lymphoma (30.3 +/- 15.0% in B-cell NHL, and 37.4 +/- 18.6% in HD) than in reactive hyperplasia (54.7 +/- 13.2%), leading to the conclusion of an accumulation of immune cells in tumor microenvironment. A further heterogeneity in the relative proportion of naive and memory TIL-T was also observed within lymphoma (range: 11 to 68% in B-cell NHL, 5 to 69% in HD). In B-cell NHL, it was related to histological features, as documented by the Kiel classification (P = .028), and to a stronger extent to cytological characteristics analysed with the Grenoble classification (P less than .0001): class 1 NHL, which are essentially indolent NHL displayed lower naive cells (22.2 +/- 7.4%) than class 3 NHL, which are more aggressive (40.1 +/- 16.1%). Among the monoclonal antibodies (mAb) defining the B-cell clone phenotype or activation state (CD19, CD20, CD21, CD22, CD23, CD24, CD5, CD10, CD11a, and Ki67), only CD23 (P = .0003) and Ki67 (P = .0007) revealed statistical association with the percentage of naive CD4 lymphocytes. No correlation could be demonstrated with the proportion of whole TIL-T, activated CD3 DR TIL-T, or CD4 subset.
authors.affiliation: Laboratoire d'immunocytologie, Centre de Transfusion Sanguine de Grenoble, La tronche, France.
authors.forename: M C
authors.initials: MC
authors.lastname: Jacob
authors.forename: M
authors.initials: M
authors.lastname: Favre
authors.forename: F
authors.initials: F
authors.lastname: Lemarc'Hadour
authors.forename: M F
authors.initials: MF
authors.lastname: Sotto
authors.forename: T
authors.initials: T
authors.lastname: Bonnefoix
authors.forename: J J
authors.initials: JJ
authors.lastname: Sotto
authors.forename: J C
authors.initials: JC
authors.lastname: Bensa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal; D015703:Antigens, CD / Q000032:analysis* / Q000276:immunology; D015704:CD4 Antigens / Q000032:analysis* / Q000276:immunology; D002452:Cell Count; D005260:Female; D005455:Fluorescent Antibody Technique; D006649:Histocompatibility Antigens / Q000032:analysis* / Q000276:immunology; D006689:Hodgkin Disease / Q000145:classification / Q000276:immunology / Q000473:pathology*; D006801:Humans; D007156:Immunologic Memory; D017493:Leukocyte Common Antigens; D016393:Lymphoma, B-Cell / Q000235:genetics / Q000276:immunology / Q000473:pathology*; D008228:Lymphoma, Non-Hodgkin / Q000145:classification / Q000276:immunology / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D013601:T-Lymphocytes / Q000737:chemistry* / Q000276:immunology / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D015704:CD4 Antigens; D006649:Histocompatibility Antigens; D017493:Leukocyte Common Antigens